Zhong et al. evaluated the efficacy and safety of neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel therapy in patients with HER2-positive breast cancer, with an overall pCR rate of 57.1% (12/21). Here, ERBB2 is linked to breast cancer.